BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
BioMarin (NASDAQ: BMRN) will host a conference call and webcast on Monday, May 4, 2026 at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a general business update.
Rhea-AI Summary
BioMarin (NASDAQ: BMRN) will host a conference call and webcast on Monday, May 4, 2026 at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a general business update. Alexander Hardy, president and CEO, will host the call.
Dial-in and replay numbers are provided and a live audio webcast and one-week replay will be available via the investor site: https://investors.biomarin.com/.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BMRN
In the Apr 27 session, BMRN gained 1.18%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- 2025 total revenue
- $3.22B
- Full-year 2025, up 13% year-over-year
- Q4 2025 revenue
- $875M
- Fourth quarter 2025, up 17% year-over-year
- VOXZOGO revenue
- $927M
- Full-year 2025 product revenue, up 26%
- Enzyme Therapies revenue
- $2.105B
- Full-year 2025 segment revenue, up 9%
- 2026 revenue guidance
- $3.325–3.425B
- Total revenues guidance for 2026, excluding Amicus
- 2026 EPS guidance
- $4.95–5.15
- Non-GAAP diluted EPS guidance for 2026, excluding Amicus
- Amicus acquisition value
- $4.8B
- All-cash agreement to acquire Amicus Therapeutics
- Inozyme acquisition value
- $270M
- Completed acquisition of Inozyme Pharma
Previous Conferences,earnings Reports
-
Announced Q4 and full-year 2025 results call and webcast timing.
-
Scheduled Q2 2025 financial results call with webcast access details.
-
Set date and time for Q1 2025 financial results call and update.
-
Announced Q4 2024 and full-year 2024 results call and webcast details.
-
Announced Q3 2024 financial results call with replay information.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dial-in Number
International Dial-in Number: 646-307-1963
Conference Call ID: 3424435
International Replay Dial-in Number: 609-800-9909
Playback ID: 3424435
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the
Contacts: | ||
Investors | Media | |
Traci McCarty | Marni Kottle | |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. | |
(415) 455-7558 | (650) 374-2803 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-monday-may-4-2026-at-430pm-et-302753431.html
SOURCE BioMarin Pharmaceutical Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.